A Study of SCY-078 (Ibrexafungerp) to Treat People with Cancer Who Have Fungal Diseases that Persist Despite Standard Antifungal Therapy

Share

Full Title

Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI) (WIRB)

Purpose

Certain cancer treatments, such as chemotherapy, can lower white blood cell counts and make people susceptible to fungal infections. In this study, researchers are evaluating an investigational antifungal treatment called SCY-078 (ibrexafungerp) in people treated for cancer who have fungal infections that persist despite standard antifungal treatments. SCY-078 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have a fungal infection that does not go away or gets worse despite treatment.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Yeon Joo Lee at 212-639-8180.

Protocol

20-514

Phase

III

Disease Status

Newly Diagnosed

Investigator

Diseases